A Randomized, Double-Blind, Placebo Controlled, Cross-over Study of the Effectiveness of Immune Globulin Intravenous (Human), 10% (IGIV, 10%) for the Treatment of Multifocal Motor Neuropathy

Trial Profile

A Randomized, Double-Blind, Placebo Controlled, Cross-over Study of the Effectiveness of Immune Globulin Intravenous (Human), 10% (IGIV, 10%) for the Treatment of Multifocal Motor Neuropathy

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Nov 2017

At a glance

  • Drugs Immune globulin (Primary)
  • Indications Multifocal motor neuropathy
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Baxalta; Baxter Corporation
  • Most Recent Events

    • 27 Apr 2012 Primary endpoint 'Strength' has been met.
    • 27 Apr 2012 Primary endpoint 'UK-Neurological-Disability-Scale' has been met.
    • 27 Apr 2012 Results published in a Baxter International media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top